Labcorp and its Specialty Testing Group, a fully integrated portfolio of specialty and esoteric testing laboratories.
To detect EGFR gene mutations in non-small cell lung cancer tumor cells; knowing whether a mutation is present in the cells can help determine if EGFR-targeted tyrosine kinase inhibitors such as gefitinib and erlotinib may be beneficial for treating the tumor.
When you have been diagnosed with non-small cell lung cancer; when you are being treated with an EGFR-targeted tyrosine kinase inhibitor, but the cancer progresses
A sample of cancer cells from a biopsy or surgical removal of cancerous tissue; a blood sample drawn from a vein (liquid biopsy) may be used in some situations.
In many cases preparation is minimal, but it will depend upon how the cancer cells are being obtained. You will receive instructions from your healthcare practitioner based on the procedure being used to obtain the sample.
EGFR is a short name for the Epidermal Growth Factor Receptor gene. DNA from tumor cells is tested for mutations in this gene. In certain situations, DNA that has been shed from tumor cells in one's blood can also be tested and may be informative (liquid biopsy).
The EGFR gene provides instructions for a cell to make a specialized type of protein called a receptor, which is located on the surface of the cell. A receptor recognizes and binds to other substances, and the binding typically has a specific effect on the cells. EGFR is one of a group of receptors called receptor tyrosine kinases that help regulate cell growth, division, survival, and death. This regulation is a very complex process. Receptor tyrosine kinases like EGFR transmit signals from the surface of the cell to pathways within the cell.
In normal cells, binding of epidermal growth factor to its receptor on the cell surface is an important signal that can promote cell growth and proliferation. Certain mutations called "activating mutations" in the EGFR gene can result in excessive signaling for growth and uncontrolled proliferation of cancer cells.
Treatments that target EGFR are an effective therapy for certain cancers. Examples of EGFR-targeted therapy include drugs such as gefitinib and erlotinib, which are small molecules called tyrosine kinase inhibitors (TKIs) that enter cancer cells and impede signaling through the EGFR pathway. These drugs have been shown to be useful in treating non-small cell lung cancer (NSCLC), if the tumor has a mutation making it sensitive to the drug. If one of these sensitizing mutations is detected with an EGFR mutation test, then EGFR-targeted tyrosine kinase inhibitors are much more likely to be of benefit for treating the tumor.
This test is helpful to direct therapy. It detects the presence of mutations in the EGFR gene in the DNA of the tumor cells to help determine whether someone with non-small cell lung cancer (NSCLC) may benefit from targeted therapy with tyrosine kinase inhibitors (TKIs) such as gefitinib or erlotinib. Specific EGFR mutations can lead to uncontrolled growth of cancer cells. TKIs can block the action of EGFR to inhibit cancer cell growth.
An EGFR mutation test may be ordered by itself or as part of a panel (a series of tests to detect mutations in other genes such as KRAS, ALK and ROS1). Each of these tests may be used to help determine whether a person's lung cancer will respond to targeted therapy and which type will be of more benefit.
Additionally, testing may be used after treatment is initiated to determine whether the cancer has acquired new mutations that make it resistant to the current treatment. For example, one of the known resistance mutations, specifically T790M, may be detected and can then be targeted with a different drug that has been designed especially for this particular mutation.
EGFR mutation testing is ordered after an individual has been diagnosed with non-small cell lung cancer, especially adenocarcinoma.
When a patient has already been treated with an EGFR-targeted tyrosine kinase inhibitor but does not appear to be responding favorably to the treatment, the healthcare practitioner may order additional EGFR mutation testing on a new sample, to check for specific EGFR mutations that may account for lack of a favorable response. A new sample of tumor tissue, or sometimes a blood sample, is required to determine whether the cancer has acquired new mutations that make it resistant to the current treatment.
If an individual's lung cancer has an sensitizing EGFR mutation, then an EGFR-targeted tyrosine kinase inhibitor (TKI) may be effective in treating the tumor. If no sensitizing mutation is detected by the EGFR test, then the tumor is less likely to respond to TKI therapy. Sometimes an EGFR mutation is detected, but it indicates that the cancer will not respond to a TKI. Pathologists and cancer specialists (oncologists) help interpret the precise significance of the exact EGFR mutation identified for each patient.
EGFR mutation testing is usually optimized to detect EGFR mutations that have demonstrated significance, but there may be uncommon or unique EGFR mutations present in a tumor that are not detected.
Although a mutation may be present in the tumor cells, if there is very little tumor tissue and/or when there are insufficient tumor cells present that contain the mutation, the test may result in "no mutation detected" despite the mutation being present in a minority of tumor cells.
Because the amount of tumor DNA in a blood sample is uncertain, testing a blood sample (also called a liquid biopsy) is generally not preferred. However, in situations where insufficient tumor cells are available for molecular testing from a tissue biopsy, or in situations where a tissue biopsy is not able to be taken, a blood test (liquid biopsy) may be an acceptable alternative testing method.
The well-known sensitizing EGFR mutations typically result in changes to small areas of EGFR protein. Testing for these types of mutations is commonly done by techniques such as real-time PCR or next-generation sequencing.
ALK and/or ROS1 mutation testing are recommended to determine whether a person's tumor would be likely to respond to specific targeted therapies that are effective when an ALK or ROS1 mutation is detected. Testing for mutations in other genes (e.g., KRAS) may be offered for lung cancer patients if there is enough tissue sample available.
EGFR mutation testing is not available in every laboratory. If a healthcare practitioner sends a sample to a reference laboratory and depending on the test method used, the results may take a few days to several days before they are available.
For diagnosis of your tumor, you will need a conventional tissue biopsy. In addition, blood tests for circulating tumor DNA (ctDNA), also called liquid biopsies, may be done to detect EGFR mutations in the tumor that can predict potential responsiveness or resistance to targeted therapies.
Also, patients may wish to consult their health insurance company as to whether this blood testing would be covered.
EGFR and HER-2 are both members of the same family of cell membrane receptors. When either EGFR or HER-2 is significantly increased in a cancer, it often indicates a more aggressive tumor and a poorer patient prognosis. The primary differences between EGFR and HER-2 testing are that they are ordered to help evaluate different types of cancer and that the drugs that have been developed to target them are specific for that particular receptor, EGFR or HER-2. HER-2 is evaluated in breast cancer and cancer of the stomach and esophagus (gastroesophageal adenocarcinoma).
There are tests available that identify other changes in EGFR known as gene amplification, which means an abnormally increased number of copies of the EGFR gene are present in the tumor cells. Another type of test looks at the amount of EGFR protein present on the tumor cells. These tests are not helpful for identifying patients with lung cancer who may benefit from EGFR-targeted tyrosine kinase inhibitor therapy. However, they may have a role in other types of cancer. For example, sometimes tests for EGFR gene amplification are used to determine the likely course (prognosis) of cancer of the head and neck.
Other types of cancer that may have increased EGFR protein present include colon cancer, glioblastoma (a type of brain cancer), and cancers of the head and neck, breast, and pancreas. EGFR blocking agents are routinely used for treatment of metastatic colon cancer and are used with some head and neck cancers. The utility of EGFR inhibitors and their correlation with EGFR mutations in different types of cancers hasn't been fully established but continues to be investigated.
Sources Used in Most Recent Review
2018 review performed by Gregary T. Bocsi, DO.
Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, Jenkins RB, Kwiatkowski DJ, Saldivar JS, Squire J, Thunnissen E, Ladanyi M. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med. 2013 Jun;137(6):828-60. Available online at http://www.archivesofpathology.org/doi/pdf/10.5858/arpa.2012-0720-OA.
Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker E, Colasacco C, Dacic S, Hirsch FR, Kerr K, Kwiatkowski DJ, Ladanyi M, Nowak JA, Sholl L, Temple-Smolkin R, Solomon B, Souter LH, Thunnissen E, Tsao MS, Ventura CB, Wynes MW, Yatabe Y. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch Pathol Lab Med. 2018 Jan 22. Available online at http://www.archivesofpathology.org/doi/pdf/10.5858/arpa.2017-0388-CP.
Mishra R, Hanker AB, Garrett JT. Genomic alterations of ERBB receptors in cancer: clinical implications. Oncotarget. 2017 Nov 30;8(69):114371-114392.
(August 27, 2007) NCCN Guidelines Version 2.2018 Panel Members. Non-Small Cell Lung Cancer. NCCN Clinical Practice Guidelines in Oncology. Available online at https://www.nccn.org/professionals/physician_gls/default.aspx. Accessed on 1/31/2018
(© 2018). EGFR T790M Mutation in Circulating Tumor DNA by Digital Droplet PCR. ARUP Laboratories. Available online at https://www.aruplab.com/T790M. Accessed June 2019.
Bronner, M. Revolutionizing Treatment for Cancer Care: New Circulating Cell-Free Tumor DNA (ctDNA)Technology. ARUP Laboratories. Available online at https://www.aruplab.com/files/resources/news/ExpertEdge_Bronner.pdf. Accessed June 2019.
Sources Used in Previous Reviews
Thomas, Clayton L., Editor (1997). Taber's Cyclopedic Medical Dictionary. F.A. Davis Company, Philadelphia, PA [18th Edition].
Pagana, Kathleen D. & Pagana, Timothy J. (2001). Mosby's Diagnostic and Laboratory Test Reference 5th Edition: Mosby, Inc., Saint Louis, MO.
(2004 April). EGFR by FISH. ARUP Technical Bulletin [On-line information]. PDF available for dowload at http://www.arup-lab.com/media/pdf/testing/tech_bulletins/egfr_apr04.pdf.
(© 2004). EGFR by FISH. ARUP's Guide to Clinical Laboratory Testing [On-line information]. Available online at http://www.aruplab.com/guides/clt/tests/clt_a213.jsp#3635067.
Check, W. (2004 January). New school of FISH: solid tumor testing. CAP Cover Story [On-line journal article]. Available online at http://www.cap.org/apps/docs/cap_today/cover_stories/0104NewSchoolOfFISH.html.
(2004). Epidermal Growth Factor Receptor Assay, Iressa (Gefitinib) responsiveness in lung cancer, EGFR Gene Analysis. Clinical Molecular Diagnostic Laboratory [On-line information]. Available Online at http://www.cityofhope.org/cmdl/EGFR.asp.
(© 2003). Epidermal Growth Factor Receptor (EGFR), Breast Cancer. LabCorp [On-line test information]. Available Online at http://www.labcorp.com/datasets/labcorp/html/chapter/.
(2004 April 29). Discovery Promises Better Use of Iressa for Lung Cancer. American Cancer Society, ACS News Center [On-line article]. Available online at http://www.cancer.org/docroot/NWS/content/NWS_1_1x_Discovery_Promises_Better_Use_of_Iressa_for_Lung_Cancer.asp.
Ang, K. et. al. (2002 December 15). Impact of Epidermal Growth Factor Receptor Expression on Survival and Pattern of Relapse in Patients with Advanced Head and Neck Carcinoma. Cancer Research 62, 7350-7356 [On-line journal]. Available Online at http://cancerres.aacrjournals.org/cgi/content/full/62/24/7350.
(2004 April 29). Presence of Gene Mutation Tightly Linked to Drug Effectiveness in Lung Cancer. National Cancer Institute [On-line news]. Available Online at http://www.cancer.gov/newscenter/pressreleases/IressaMutation.
Billingsley, J. (2003 December 6). New Clue to Breast Cancer Mortality, Growth factor identified with poorer outcomes in patients. Henry Ford Health System [On-line news]. Available Online at http://www.henryfordhealth.org/110736.cfm.
Langreth, R. (2004 April 29). Gene Predicts Cancer Drug Effectiveness. Forbes.com Pharmaceuticals [On-line article]. Available Online at http://www.forbes.com/2004/04/29/cx_rl_0429cancer_print.html.
(2003). Epidermal Growth Factor Receptor Status in Breast Cancer Metastases to the Central Nervous System - Comparison With HER-2/neu Status. CAP [On-line Abstracts From the College of American Pathologists 2003 Annual Meeting (CAP '03)]. Available Online at http://www.cap.org/apps/docs/archives_pathology_lab_med/this_month.html.
Weaver, C. and Maxon, J. (1998- 2004). Targeting Epidermal Growth Factor Receptor Pathways. CancerConsultants.com Current Topics in Oncology [On-line information]. Available online at http://www.411cancer.com/syndication/veContent.jsp?ArticleID=egfr_02&ArticleTypeID=CTON.
Kuriyan, J. (2006 June 16). Researchers Learn How Epidermal Growth Factor Receptor Is Activated. Howard Hughes Medical Institute [On-line information]. Available online at http://www.hhmi.org/news/kuriyan20060615.html. Accessed on 7-30-08.
American Cancer Society [On-line information]. (2007 May 14, Revised). Detailed Guide: Laryngeal and Hypopharyngeal Cancer. What's New in Laryngeal and Hypopharyngeal Cancer Research and Treatment? Available online through http://www.cancer.org. Accessed on 7-30-08.
Chu, E. et. al. (2007 July 25). Expanding Scientific Evidence for Epidermal Growth Factor Receptor-Directed Therapy in Colorectal Cancer and Squamous Cell Carcinoma of the Head and Neck CME. Medscape Today [On-line information]. Available online at http://www.medscape.com/viewprogram/7463. Accessed on 7-30-08.
Dacic, S. et. al. (2006 June 6). Significance of EGFR Protein Expression and Gene Amplification in Non-Small Cell Lung Carcinoma. Medscape from Am J Clin Pathol. 2006;125(6):860-865 [On-line information]. Available online at http://www.medscape.com/viewarticle/532262. Accessed on 7-30-08.
Grody, W. (2007 January 30). ASCP 2006: Applications of Molecular Methods in Surgical Pathology CME/CMLE. Medscape [On-line information]. Available online at http://www.medscape.com/viewarticle/551100. Accessed on 7-30-08.
Timothy S. Uphoff, PhD, D(ABMG), MLS(ASCP)CM. Section Head Molecular Pathology Laboratory, Marshfield Clinic, Marshfield WI.
Cheng, L. et. al. (2011 May 31). The Landscape of EGFR Pathways and Personalized Management of Non-small-cell Lung Cancer. Medscape Today News from Future Oncology. 2011;7(4):519-541 [On-line information]. Available online at http://www.medscape.com/viewarticle/740715_2. Accessed.December 2013
Grenache, D. et. al. (Updated 2013 November). Lung Cancer. ARUP Consult [On-line information]. Available online at http://www.arupconsult.com/Topics/LungCancer.html?client_ID=LTD#tabs=0. Accessed December 2013.
(© 1995-2013). Test ID: FEGFR91903 EGFR Mutation Analysis in NSCLC. Mayo Clinic Mayo Medical Laboratories [On-line information]. Available online at http://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/61247. Accessed December 2013.
Chen, Y. (Updated 2011 August 24). Lung cancer - non-small cell. MedlinePlus Medical Encyclopedia [On-line information]. Available online at http://www.nlm.nih.gov/medlineplus/ency/article/007194.htm. Accessed December 2013.
Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. Burtis CA, Ashwood ER, Bruns DE, eds. St. Louis: Elsevier Saunders; 2006, Pp 779-780.
(Updated May 22, 2013) American Cancer Society. Targeted Therapy. Available online at http://www.cancer.org/cancer/lungcancer-non-smallcell/detailedguide/non-small-cell-lung-cancer-treating-targeted-therapies. Accessed December 2013.
Raparia K, et al. Molecular Profiling in Non–Small Cell Lung Cancer: A Step Toward Personalized Medicine. Archives of Pathology & Laboratory Medicine 2013 137:4, 481-491. Available online at http://www.archivesofpathology.org/doi/full/10.5858/arpa.2012-0287-RA. Accessed December 2013.
(July 15, 2013) Markman M. Genetics of Non-Small Cell Lung Cancer. Medscape Reference article. Available online at http://emedicine.medscape.com/article/1689988-overview. Accessed December 2013.
(Oct 21, 2013) Tan W. Non-small Cell Lung Cancer. Medscape Reference article. Available online at http://emedicine.medscape.com/article/279960-overview. Accessed December 2013.
Lindeman N, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol. 2013 Jul;8(7):823-59.